GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » Debt-to-EBITDA

Amcad Biomed (ROCO:4188) Debt-to-EBITDA : -0.27 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amcad Biomed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$5.27 Mil. Amcad Biomed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$9.55 Mil. Amcad Biomed's annualized EBITDA for the quarter that ended in Mar. 2024 was NT$-54.56 Mil. Amcad Biomed's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.27.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Amcad Biomed's Debt-to-EBITDA or its related term are showing as below:

ROCO:4188' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.75   Med: -0.29   Max: 0
Current: -0.57

ROCO:4188's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs ROCO:4188: -0.57

Amcad Biomed Debt-to-EBITDA Historical Data

The historical data trend for Amcad Biomed's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed Debt-to-EBITDA Chart

Amcad Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.35 -0.20 -1.75 -0.29 -0.57

Amcad Biomed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.27 -0.53 -1.32 -0.27

Competitive Comparison of Amcad Biomed's Debt-to-EBITDA

For the Medical Devices subindustry, Amcad Biomed's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's Debt-to-EBITDA falls into.



Amcad Biomed Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amcad Biomed's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.51 + 9.991) / -25.561
=-0.57

Amcad Biomed's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.271 + 9.546) / -54.56
=-0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Amcad Biomed  (ROCO:4188) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Amcad Biomed Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Amcad Biomed's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Amcad Biomed (ROCO:4188) Business Description

Traded in Other Exchanges
N/A
Address
No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, a software solution for thyroid nodules analysis; AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals; AmCAD- U.S, a software device for viewing and quantifying ultrasound image data of backscattered signals; and AmCAD-UO offers detection for obstructive sleep apnea on awake patients to identify the root cause of sleep apnea. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from China.

Amcad Biomed (ROCO:4188) Headlines

No Headlines